The proglucagon-derived peptides Proglucagon-derived peptides (PGDPs) are generated by differential posttranslational processing of the precursor proglucagon in the pancreas, intestine, and brain. Although glucagon is the principal PGDP produced in α cells of the islets, prohormone convertase 1 (PC1) generates glicentin, oxyntomodulin, GLP1, and GLP2 from proglucagon in enteroendocrine L cells. The importance of PC1 processing of proglucagon in enteroendocrine L cells is illustrated by the phenotype of PC1-deficient mice, which exhibit multiple defects in prohormone processing, including a lack of substantial amounts of mature bioactive GLP1 and GLP2. Although most PGDP-expressing cells are located in the distal bowel and colon, there are also cells in the more proximal regions of the small bowel that produce both GLP1 and GIP. Nutrient ingestion potently upregulates intestinal expression of the gene encoding proglucagon and the secretion of PGDPs, and a high-fiber diet ( 26), protein hydrolysates, and short-chain fatty acids increase levels of mRNA encoding proglucagon in enteroendocrine L cells ( 27, 28). Intestinal injury and resection are both associated with elevated circulating levels of PGDPs and increased levels of proglucagon mRNA in the remnant intestine ( 29, 30). PGDP secretion by enteroendocrine L cells is stimulated by neural signals, peptide hormones such as GIP (in rodents but not humans), and direct nutrient contact ( 31).
GLP1. GLP1 circulates as 2 equipotent forms, GLP1 7-37 and GLP1 7-36amide ( 32– 34), but most circulating GLP1 in humans is GLP1 7-36amide ( 35). Plasma levels of full-length GLP1 are typically within the 5- to 10-pM range in the fasting state and increase to approximately 50 pM after meal ingestion ( 35, 36). A small, but detectable, defect in meal-stimulated GLP1 secretion has been observed in subjects with obesity or T2DM about 60–120 minutes after food consumption ( 36). Clearance of GLP1 has received considerable attention because of the therapeutic potential of the peptide. The half-life of circulating native bioactive GLP1 is less than 2 minutes ( 37, 38), mostly because it is cleared by the kidney and degraded by DPP4.
GLP1 exerts multiple physiological actions leading to control of energy intake and nutrient assimilation ( 1) (Table 1). The original physiological role described for GLP1 was that of an incretin hormone that stimulates insulin secretion in a glucose-dependent manner ( 39– 41). GLP1 also increases transcription of the gene encoding insulin and enhances both the stability of the mRNA encoding insulin and biosynthesis of insulin by mechanisms that involve pathways that are both dependent on and independent of cAMP and protein kinase A, as well as pathways that increase the intracellular concentration of Ca 2+ (Table 1). GLP1 also improves β cell function by inducing increased expression of sulfonylurea receptor and inwardly rectifying K + channel (KIR6.2) in β cells. It also prevents the downregulation of mRNA encoding KIR6.2 and the downregulation of ATP-sensitive K + channel activity induced by high levels of glucose.
The physiological importance of endogenous GLP1 has been demonstrated using GLP1R antagonists, immunoneutralizing antisera, and Glp1r–/– mice. Elimination of GLP1 activity with GLP1-immunoneutralizing antisera or the GLP1R antagonist exendin 9–39, which is a truncated form of the lizard GLP1-related peptide exendin-4, results in impaired glucose tolerance, and diminished glucose-stimulated insulin levels in both animals and humans ( 17, 42– 44). Furthermore, basal GLP1 signaling in the fasting state is essential for regulation of glucose homeostasis, because infusion of exendin 9-39 increases levels of fasting glucose and glucagon in human subjects, demonstrating that even low basal levels of GLP1 exert a tonic inhibitory effect on glucagon-secreting α cells ( 45). Similarly, Glp1r–/– mice are glucose intolerant and have defective glucose-stimulated insulin secretion and fasting hyperglycemia ( 46).
The insulinotropic and glucagonostatic effects of GLP1 depend on elevated levels of plasma glucose, thereby reducing the likelihood that treatment of diabetic subjects with GLP1R agonists would lead to hypoglycemia. In in vitro islet studies, GLP1 confers glucose sensitivity to β cells and improves the number of β cells able to respond to glucose. However, GLP1R signaling is not essential for β cells to sense glucose in mouse islets ( 47). The demonstration that GLP1 upregulates molecular components of the glucose-sensing system in β cells (that is, glucose transporters, ATP-sensitive K + channels, and glucokinase) might provide a partial mechanism for understanding the effects of GLP1 on the glucose responsiveness of β cells ( 48, 49). Furthermore, short-term exposure to GLP1R agonists markedly improves glucose-stimulated insulin secretion in patients with T2DM ( 50– 52).
GLP1 also promotes the proliferation and neogenesis of β cells, reduces β cell apoptosis, and increases differentiation of exocrine-like cells toward a more differentiated β cell phenotype ( 2, 53– 57). Conversely, elimination of mouse GLP1R signaling is associated with reduced numbers of large β cell clusters and alterations in α cell topography ( 58). Furthermore, following partial pancreatectomy, Glp1r–/– mice exhibit a reduced adaptive islet-regenerative response and greater hyperglycemia than littermate controls ( 59). Glp1r–/– mice are also more sensitive to the cytotoxic and diabetogenic actions of streptozotocin ( 60). The signal transduction pathways whereby GLP1 mediates its proliferative effects have not been completely defined but involve PI3K, EGFR transactivation, and p38 MAPK and PKCζ ( 61, 62). Furthermore, GLP1 also activates a transcriptional program critical for cell survival; and pancreatic and duodenal homeobox gene 1 (PDX1), FOXO1, and insulin receptor substrate 2 (IRS2) have been identified as essential downstream targets for GLP1R-dependent cytoprotection in β cells ( 60, 63, 64). GLP1 also reduces the expression of proapoptotic genes, enhances glucose-stimulated insulin secretion, and prevents apoptosis induced by high levels of glucose and/or palmitate in human β cells through mechanisms involving AKT ( 65, 66).
Biological actions of glicentin, oxyntomodulin, and GLP2. Glicentin is a 69–amino acid PGDP that contains the 29–amino acid sequence of glucagon flanked by peptide extensions at both the amino and the carboxyl terminus. Although secreted together with GLP1 and GLP2 from enteroendocrine L cells, glicentin has not been shown to regulate glucose homeostasis. Oxyntomodulin also contains the 29–amino acid sequence of glucagon with an additional 8–amino acid carboxy-terminal extension. Oxyntomodulin stimulates intestinal glucose uptake ( 67) and insulin secretion ( 68) and inhibits gastric emptying, food intake, and meal-stimulated gastric acid secretion. Oxyntomodulin also induces satiety, inhibits food intake, and increases energy expenditure in humans ( 69, 70). Although oxyntomodulin is a weak agonist of both GLP1R and the glucagon receptor, the anorectic actions of oxyntomodulin are blocked by the GLP1R antagonist exendin 9-39 ( 71) and are eliminated in the absence of a functional GLP1R ( 72). Therefore, it seems that many of the pharmacological actions of oxyntomodulin represent heterologous activation of related PGDP receptors.
GLP2 is a 33–amino acid peptide secreted with GLP1 from enteroendocrine cells in a nutrient-dependent manner. GLP2 rapidly induces hexose transport in jejunal basolateral membrane vesicles ( 73). The main biological consequence of exogenous GLP2 administration is expansion of the mucosal epithelium in the small bowel. The intestinotrophic actions of GLP2 have been demonstrated in rodents with intestinal injury ( 74, 75) and in humans with short bowel syndrome ( 76– 78). Although acute GLP2 administration increased levels of plasma glucagon, triglycerides, and FFAs in the postprandial state ( 79), there is no evidence that acute or chronic GLP2 administration directly regulates insulin secretion or glucose homeostasis in humans ( 76).
|
References 1. Drucker, D.J. The biology of incretin hormones. Cell Metab. 2006;3:153–165. [PubMed]2. Drucker, D.J. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. . Mol. Endocrinol. 2003;17:161–171. [PubMed]3. Riddle, M.C.; Drucker, D.J. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care. 2006;29:435–449. [PubMed]4. Dupre, J.; Ross, S.A.; Watson, D.; Brown, J.C. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J. Clin. Endocrinol. Metab. 1973;37:826–828. [PubMed]5. Pederson, R.A.; Schubert, H.E.; Brown, J.C. Gastric inhibitory polypeptide. Its physiologic release and insulinotropic action in the dog. Diabetes. 1975;24:1050–1056. [PubMed]6. Usdin, T.B.; Mezey, E.; Button, D.C.; Brownstein, M.J.; Bonner, T.I. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology. 1993;133:2861–2870. [PubMed]7. Mayo, K.E., et al. International Union of Pharmacology. XXXV. The glucagon receptor family. . Pharmacol. Rev. 2003;55:167–194. [PubMed]8. Yip, R.G.; Boylan, M.O.; Kieffer, T.J.; Wolfe, M.M. Functional GIP receptors are present on adipocytes. Endocrinology. 1998;139:4004–4007. [PubMed]9. Mentlein, R.; Gallwitz, B.; Schmidt, W.E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 1993;214:829–835. [PubMed]10. Kieffer, T.J.; McIntosh, C.H.; Pederson, R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. . Endocrinology. 1995;136:3585–3596. [PubMed]11. Deacon, C.F.; Nauck, M.A.; Meier, J.; Hucking, K.; Holst, J.J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J. Clin. Endocrinol. Metab. 2000;85:3575–3581. [PubMed]12. Gromada, J., et al. Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes. 1998;47:57–65. [PubMed]13. Trumper, A., et al. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. Mol. Endocrinol. 2001;15:1559–1570. [PubMed]14. Trumper, A.; Trumper, K.; Horsch, D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J. Endocrinol. 2002;174:233–246. [PubMed]15. Kim, S.J., et al. GIP stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3-K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1 and downregulation of bax expression. J. Biol. Chem. 2005;280:22297–22307. [PubMed]16. Tseng, C.C.; Kieffer, T.J.; Jarboe, L.A.; Usdin, T.B.; Wolfe, M.M. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J. Clin. Invest. 1996;98:2440–2445. [PubMed]17. Baggio, L.; Kieffer, T.J.; Drucker, D.J. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice. Endocrinology. 2000;141:3703–3709. [PubMed]18. Miyawaki, K., et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 1999;96:14843–14847. [PubMed]19. Miyawaki, K., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 2002;8:738–742. [PubMed]20. Gault, V.A., et al. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes. 2005;54:2436–2446. [PubMed]21. Nauck, M.A., et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 1993;91:301–307. [PubMed]22. Elahi, D., et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul. Pept. 1994;51:63–74. [PubMed]23. Fehmann, H.-C.; Goke, R.; Goke, B. Cell and molecular biology of the incretin hormones glucagon-like peptide 1 and glucose-dependent releasing polypeptide. Endocr. Rev. 1995;16:390–410. [PubMed]24. Lynn, F.C., et al. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes. 2001;50:1004–1011. [PubMed]25. Meier, J.J., et al. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes. 2004;53(Suppl. 3):S220–S224. [PubMed]26. Reimer, R.A.; McBurney, M.I. Dietary fiber modulates intestinal proglucagon messenger ribonucleic acid and postprandial secretion of glucagon-like peptide-1 and insulin in rats. Endocrinology. 1996;137:3948–3956. [PubMed]27. Tappenden, K.A.; Thomson, A.B.; Wild, G.E.; McBurney, M.I. Short-chain fatty acids increase proglucagon and ornithine decarboxylase messenger RNAs after intestinal resection in rats. JPEN J. Parenter. Enteral Nutr. 1996;20:357–362. [PubMed]28. Tappenden, K.A.; McBurney, M.I. Systemic short-chain fatty acids rapidly alter gastrointestinal structure, function, and expression of early response genes. Dig. Dis. Sci. 1998;43:1526–1536. [PubMed]29. Ulshen, M.H., et al. Increased ileal proglucagon expression after jejunectomy is not suppressed by inhibition of bowel growth. Dig. Dis. Sci. 1996;41:677–683. [PubMed]30. Taylor, R.G.; Beveridge, D.J.; Fuller, P.J. Expression of ileal glucagon and peptide tyrosine-tyrosine genes. Response to inhibition of polyamine synthesis in the presence of massive small-bowel resection. Biochem. J. 1992;286:737–741. [PubMed]31. Brubaker, P.L.; Anini, Y. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can. J. Physiol. Pharmacol. 2003;81:1005–1012. [PubMed]32. Mojsov, S.; Kopczynski, M.G.; Habener, J.F. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J. Biol. Chem. 1990;265:8001–8008. [PubMed]33. Orskov, C.; Wettergren, A.; Holst, J.J. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. . Diabetes. 1993;42:658–661. [PubMed]34. Wettergren, A.; Pridal, L.; Wojdemann, M.; Holst, J.J. Amidated and non-amidated glucagon-like peptide-1 (GLP-1): non-pancreatic effects (cephalic phase acid secretion) and stability in plasma in humans. Regul. Pept. 1998;77:83–87. [PubMed]35. Orskov, C.; Rabenhoj, L.; Wettergren, A.; Kofod, H.; Holst, J.J. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994;43:535–539. [PubMed]36. Vilsboll, T.; Krarup, T.; Deacon, C.F.; Madsbad, S.; Holst, J.J. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609–613. [PubMed]37. Hansen, L.; Deacon, C.F.; Orskov, C.; Holst, J.J. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology. 1999;140:5356–5363. [PubMed]38. Deacon, C.F., et al. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44:1126–1131. [PubMed]39. Kreymann, B.; Williams, G.; Ghatei, M.A.; Bloom, S.R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2:1300–1304. [PubMed]40. Mojsov, S.; Weir, G.C.; Habener, J.F. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 1987;79:616–619. [PubMed]41. Orskov, C.; Holst, J.J.; Nielsen, O.V. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. . Endocrinology. 1988;123:2009–2013. [PubMed]42. D’alessio, D.A., et al. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J. Clin. Invest. 1996;97:133–138. [PubMed]43. Edwards, C.M., et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes. 1999;48:86–93. [PubMed]44. Wang, Z., et al. Glucagon-like peptide 1 is a physiological incretin in rat. J. Clin. Invest. 1995;95:417–421. [PubMed]45. Schirra, J., et al. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J. Clin. Invest. 1998;101:1421–1430. [PubMed]46. Scrocchi, L.A., et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. Nat. Med. 1996;2:1254–1258. [PubMed]47. Flamez, D., et al. Mouse pancreatic beta cells exhibit preserved glucose competence after disruption of the glucagon-like peptide 1 receptor gene. Diabetes. 1998;47:646–652. [PubMed]48. Wang, Y.H., et al. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology. 1995;136:4910–4917. [PubMed]49. Wang, Y., et al. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J. Clin. Invest. 1997;99:2883–2889. [PubMed]50. Zander, M.; Madsbad, S.; Madsen, J.L.; Holst, J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824–830. [PubMed]51. Degn, K.B., et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53:1187–1194. [PubMed]52. Fehse, F., et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. . J. Clin. Endocrinol. Metab. 2005;90:5991–5997. [PubMed]53. Xu, G.; Stoffers, D.A.; Habener, J.F.; Bonner-Weir, S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270–2276. [PubMed]54. Edvell, A.; Lindstrom, P. Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/?). Endocrinology. 1999;140:778–783. [PubMed]55. Stoffers, D.A., et al. Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes. 2000;49:741–748. [PubMed]56. Perfetti, R.; Zhou, J.; Doyle, M.E.; Egan, J.M. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology. 2000;141:4600–4605. [PubMed]57. Kim, J.G., et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes. 2003;52:751–759. [PubMed]58. Ling, Z., et al. Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch. 2001;438:382–387. [PubMed]59. De Leon, D.D., et al. Role of endogenous glucagon-like peptide-1 in islet regeneration following partial pancreatectomy. Diabetes. 2003;5252:365–371. [PubMed]60. Li, Y., et al. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 2003;278:471–478. [PubMed]61. Buteau, J., et al. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes. 2001;50:2237–2243. [PubMed]62. Brubaker, P.L.; Drucker, D.J. Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut and central nervous system. Endocrinology. 2004;145:2653–2659. [PubMed]63. Park, S., et al. Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. . J. Biol. Chem. 2005;281:1159–1168. [PubMed]64. Buteau, J.; Spatz, M.L.; Accili, D. Transcription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic beta-cell mass. . Diabetes. 2006;55:1190–1196. [PubMed]65. Farilla, L., et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144:5149–5158. [PubMed]66. Buteau, J., et al. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia. 2004;47:806–815. [PubMed]67. Collie, N.L.; Zhu, Z.; Jordan, S.; Reeve, J.R. Oxyntomodulin stimulates intestinal glucose uptake in rats. Gastroenterology. 1997;112:1961–1970. [PubMed]68. Jarrousse, C.; Bataille, D.; Jeanrenaud, B. A pure enteroglucagon, oxyntomodulin (glucagon 37), stimulates insulin release in perfused rat pancreas. . Endocrinology. 1984;115:102–105. [PubMed]69. Wynne, K., et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int. J. Obes. (Lond.). 2007 In press. 70. Wynne, K., et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. . Diabetes. 2005;54:2390–2395. [PubMed]71. Dakin, C.L., et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology. 2001;142:4244–4250. [PubMed]72. Baggio, L.L.; Huang, Q.; Brown, T.J.; Drucker, D.J. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology. 2004;127:546–558. [PubMed]73. Cheeseman, C.I.; Tsang, R. The effect of gastric inhibitory polypeptide and glucagon like peptides on intestinal hexose transport. Am. J. Physiol. Gastrointest. Liver Physiol. 1996;271:G477–G482. 74. Boushey, R.P.; Yusta, B.; Drucker, D.J. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am. J. Physiol. 1999;277:E937–E947. [PubMed]75. Boushey, R.P.; Yusta, B.; Drucker, D.J. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res. 2001;61:687–693. [PubMed]76. Jeppesen, P.B., et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001;120:806–815. [PubMed]77. Jeppesen, P.B. Clinical significance of GLP-2 in short-bowel syndrome. J. Nutr. 2003;133:3721–3724. [PubMed]78. Jeppesen, P.B., et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005;54:1224–1231. [PubMed]79. Meier, J.J., et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology. 2006;130:44–54. [PubMed]80. Gutniak, M.; Orskov, C.; Holst, J.J.; Ahren, B.; Efendic, S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 1992;326:1316–1322. [PubMed]81. Rachman, J., et al. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1(7-36)amide in patients with NIDDM. Diabetes. 1996;45:1524–1530. [PubMed]82. Rachman, J.; Barrow, B.A.; Levy, J.C.; Turner, R.C. Near normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. Diabetologia. 1997;40:205–211. [PubMed]83. Todd, J.F.; Wilding, J.P.; Edwards, C.M.; Ghatei, M.A.; Bloom, S.R. Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. Eur. J. Clin. Invest. 1997;27:533–536. [PubMed]84. Eng, J.; Kleinman, W.A.; Singh, L.; Singh, G.; Raufman, J.P. Isolation and characterization of exendin 4, an exendin 3 analogue from Heloderma suspectum venom. J. Biol. Chem. 1992;267:7402–7405. [PubMed]85. Goke, R., et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J. Biol. Chem. 1993;268:19650–19655. [PubMed]86. Chen, Y.E.; Drucker, D.J. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. . J. Biol. Chem. 1997;272:4108–4115. [PubMed]87. Buse, J.B., et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628–2635. [PubMed]88. DeFronzo, R.A., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092–1100. [PubMed]89. Kendall, D.M., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083–1091. [PubMed]90. Heine, R.J., et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann. Intern. Med. 2005;143:559–569. [PubMed]91. Harder, H.; Nielsen, L.; Tu, D.T.; Astrup, A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care. 2004;27:1915–1921. [PubMed]92. Madsbad, S.; Schmitz, O.; Ranstam, J.; Jakobsen, G.; Matthews, D.R. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004;27:1335–1342. [PubMed]93. Gedulin, B.R., et al. Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia. 2005;48:1380–1385. [PubMed]94. Mitani, H.; Takimoto, M.; Hughes, T.E.; Kimura, M. Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity. Jpn. J. Pharmacol. 2002;88:442–450. [PubMed]95. Marguet, D., et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. U. S. A. 2000;97:6874–6879. [PubMed]96. Ahren, B.; Holst, J.J.; Martensson, H.; Balkan, B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur. J. Pharmacol. 2000;404:239–245. [PubMed]97. Pederson, R.A., et al. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes. 1998;47:1253–1258. [PubMed]98. Ahren, B., et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. . J. Clin. Endocrinol. Metab. 2004;89:2078–2084. [PubMed]99. Ahren, B., et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care. 2002;25:869–875. [PubMed]100. Ahren, B.; Holst, J.J.; Efendic, S. Antidiabetogenic action of cholecystokinin-8 in type 2 diabetes. J. Clin. Endocrinol. Metab. 2000;85:1043–1048. [PubMed]101. Boushey, R.P., et al. Hypoglycemia, defective islet glucagon secretion, but normal islet mass in mice with a disruption of the gastrin gene. Gastroenterology. 2003;125:1164–1174. [PubMed]102. Kuntz, E.; Pinget, M.; Damge, P. Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats. Jop. 2004;5:464–475. [PubMed]103. Rooman, I.; Lardon, J.; Bouwens, L. Gastrin stimulates beta-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes. 2002;51:686–690. [PubMed]104. Rooman, I.; Bouwens, L. Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57Bl6/J mice treated with alloxan. Diabetologia. 2004;47:259–265. [PubMed]105. Suarez-Pinzon, W.L.; Yan, Y.; Power, R.; Brand, S.J.; Rabinovitch, A. Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice. Diabetes. 2005;54:2596–2601. [PubMed]106. Suarez-Pinzon, W.L.; Lakey, J.R.; Brand, S.J.; Rabinovitch, A. Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet beta-cells from pancreatic duct cells and an increase in functional beta-cell mass. J. Clin. Endocrinol. Metab. 2005;90:3401–3409. [PubMed]107. Druce, M.R., et al. Ghrelin increases food intake in obese as well as lean subjects. Int. J. Obes. (Lond.). 2005;29:1130–1136. [PubMed]108. Prado, C.L.; Pugh-Bernard, A.E.; Elghazi, L.; Sosa-Pineda, B.; Sussel, L. Ghrelin cells replace insulin-producing beta cells in two mouse models of pancreas development. Proc. Natl. Acad. Sci. U. S. A. 2004;101:2924–2929. [PubMed]109. Dezaki, K., et al. Endogenous ghrelin in pancreatic islets restricts insulin release by attenuating Ca2+ signaling in beta-cells: implication in the glycemic control in rodents. Diabetes. 2004;53:3142–3151. [PubMed]110. Sun, Y.; Asnicar, M.; Saha, P.K.; Chan, L.; Smith, R.G. Ablation of ghrelin improves the diabetic but not obese phenotype of ob/ob mice. Cell Metab. 2006;3:379–386. [PubMed]111. Theander-Carrillo, C., et al. Ghrelin action in the brain controls adipocyte metabolism. J. Clin. Invest. 2006;116:1983–1993. doi: 10.1172/JCI25811. [PubMed]112. Irako, T., et al. Ghrelin prevents development of diabetes at adult age in streptozotocin-treated newborn rats. Diabetologia. 2006;49:1264–1273. [PubMed]113. Besterman, H.S., et al. Gut hormone release after intestinal resection. Gut. 1982;23:854–861. [PubMed]114. Besterman, H.S., et al. Gut hormones in inflammatory bowel disease. Scand. J. Gastroenterol. 1983;18:845–852. [PubMed]115. Xiao, Q.; Boushey, R.P.; Cino, M.; Drucker, D.J.; Brubaker, P.L. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am. J. Physiol. 2000;278:R1057–R1063. 116. Naslund, E.; Backman, L.; Holst, J.J.; Theodorsson, E.; Hellstrom, P.M. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes. Surg. 1998;8:253–260. [PubMed]117. Le Roux, C.W., et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann. Surg. 2006;243:108–114. [PubMed]118. Morinigo, R., et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J. Clin. Endocrinol. Metab. 2006;91:1735–1740. [PubMed]119. Patti, M.E., et al. Severe hypoglycemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia. 2005;4:2236–2240. [PubMed]120. Service, G.J., et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N. Engl. J. Med. 2005;353:249–254. [PubMed]121. Meier, J.J.; Butler, A.E.; Galasso, R.; Butler, P.C. Hyperinsulinemic hypoglycemia after gastric bypass surgery is not accompanied by islet hyperplasia or increased beta-cell turnover. Diabetes Care. 2006;29:1554–1559. [PubMed]122. Jackson, R.S., et al. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J. Clin. Invest. 2003;112:1550–1560. doi: 10.1172/JCI200318784. [PubMed]123. Wang, J., et al. Mutant neurogenin-3 in congenital malabsorptive diarrhea. N. Engl. J. Med. 2006;355:270–280. [PubMed]124. Grant, S.F., et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat. Genet. 2006;38:320–323. [PubMed]125. Florez, J.C., et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N. Engl. J. Med. 2006;355:241–250. [PubMed] |